Novel Concentrated Insulins: What Benefits and for Which Patients?

Program Goals

Guideline Recommendations for Treatment of T1DM

Pharmacokinetics of Commonly Used Insulins[a]

Insulin Development Timeline

Ultra-Fast-Acting Prandial Insulins: Clinical Development Approaches

Mean Serum Insulin Concentrations: Single Dose During a Euglycemic Clamp

Potential Impact and Consequences of Nocturnal Hypoglycemia

Timely Application of Insulin Therapy in T2DM

Commonly Prescribed Antihyperglycemics

Hazard Ratios for CV Outcomes: ORIGIN Trial—IGlar vs Standard of Care

Concentrated Insulins for SQ Use

Distribution of Insulin in SQ Tissue

IDeg U-200 vs IDeg U-100: Similar Time-Action Profiles

Reduced Hypoglycemic Events With Higher-Concentration Insulins: Results From the EDITION Trials

Prandial Insulins: Lispro U-100 and Lispro U-200: Similar Action Profiles

Concentrated Insulins: Target Patient Populations[a,b]

EDITION 3: Comparison of IGlar 300 U/mL vs IGlar 100 U/mL in Insulin-Naive Patients

BEGIN LOW VOLUME: IDeg 200 U/mL Once Daily Compared With IGlar

Medication Errors Associated With Use of Concentrated Insulins

BEGIN LOW VOLUME: Fewer Injections With IDeg

U-500R tid vs bid: Study Design

U-500R tid vs bid: HbA1c CFB

U-500R tid vs bid: Actual and CFB TDD Values

U-500 tid vs bid RCT: Body Weight CFB

U-500 tid vs bid: Severe Hypoglycemia, SAEs, TEAEs (0-24 Weeks)

Conversion Information for Humulin R U-500 (Concentrated) Insulin Dose

Sample Rx: U-500 Insulin, SQ Administration, 150-U Insulin Dose

Insulin Pen Delivery Systems

Summary